TY - JOUR
T1 - Type 2 diabetes and cognitive impairment in an older population with overweight or obesity and metabolic syndrome: baseline cross-sectional analysis of the PREDIMED-plus study
AU - Mallorquí-Bagué, Núria
AU - Lozano-Madrid, María
AU - Toledo, Estefanía
AU - Corella, Dolores
AU - Salas-Salvadó, Jordi
AU - Cuenca-Royo, Aida
AU - Vioque, Jesús
AU - Romaguera, Dora
AU - Martínez, J. Alfredo
AU - Wärnberg, Julia
AU - López-Miranda, José
AU - Estruch, Ramón
AU - Bueno-Cavanillas, Aurora
AU - Alonso-Gómez, Ángel
AU - Tur, Josep A.
AU - Tinahones, Francisco J.
AU - Serra-Majem, Lluís
AU - Martín, Vicente
AU - Lapetra, José
AU - Vázquez, Clotilde
AU - Pintó, Xavier
AU - Vidal, Josep
AU - Daimiel, Lidia
AU - Gaforio, José J.
AU - Matía, Pilar
AU - Ros, Emilio
AU - Granero, Roser
AU - Buil-Cosiales, Pilar
AU - Barragán, Rocío
AU - Bulló, Mònica
AU - Castañer, Olga
AU - García-de-la-Hera, Manoli
AU - Yáñez, Aina M.
AU - Abete, Itziar
AU - García-Ríos, Antonio
AU - Ruiz-Canela, Miguel
AU - Díaz-López, Andrés
AU - Jiménez-Murcia, Susana
AU - Martínez-González, Miguel A.
AU - De la Torre, Rafael
AU - Fernández-Aranda, Fernando
PY - 2018/12/1
Y1 - 2018/12/1
N2 - © 2018, The Author(s). This study cross-sectionally examines in the elderly population: (a) the association of type 2 diabetes with executive function (EF); (b) the effect of BMI on both type 2 diabetes and EF; (c) the association between glycaemia control and EF in type 2 diabetes. 6823 older individuals with overweight/obesity and metabolic syndrome participating in the PREDIMED-PLUS study, were assessed with a battery of cognitive tests and a medical interview. ANOVA showed a significantly worse performance on EF in type 2 diabetes vs. non-diabetic individuals. Two complementary models were displayed: (1) in the whole sample, the presence of type 2 diabetes, depressive symptoms and BMI had a direct negative effect on EF, while apnoea had an indirect negative effect; (2) in the diabetes subsample, higher illness duration was associated with worse performance in EF. Participants with type 2 diabetes and HbA1c<53 mmol/mol displayed better cognitive performance when compared to those with HbA1c≥53 mmol/mol. Our results provide a controlled comprehensive model that integrates relevant neuropsychological and physical variables in type 2 diabetes. The model suggests that, to improve treatment adherence and quality of life once diabetes has been diagnosed, cognitive decline prevention strategies need to be implemented while monitoring depressive symptoms, BMI and glycaemia control.
AB - © 2018, The Author(s). This study cross-sectionally examines in the elderly population: (a) the association of type 2 diabetes with executive function (EF); (b) the effect of BMI on both type 2 diabetes and EF; (c) the association between glycaemia control and EF in type 2 diabetes. 6823 older individuals with overweight/obesity and metabolic syndrome participating in the PREDIMED-PLUS study, were assessed with a battery of cognitive tests and a medical interview. ANOVA showed a significantly worse performance on EF in type 2 diabetes vs. non-diabetic individuals. Two complementary models were displayed: (1) in the whole sample, the presence of type 2 diabetes, depressive symptoms and BMI had a direct negative effect on EF, while apnoea had an indirect negative effect; (2) in the diabetes subsample, higher illness duration was associated with worse performance in EF. Participants with type 2 diabetes and HbA1c<53 mmol/mol displayed better cognitive performance when compared to those with HbA1c≥53 mmol/mol. Our results provide a controlled comprehensive model that integrates relevant neuropsychological and physical variables in type 2 diabetes. The model suggests that, to improve treatment adherence and quality of life once diabetes has been diagnosed, cognitive decline prevention strategies need to be implemented while monitoring depressive symptoms, BMI and glycaemia control.
UR - https://www.scopus.com/pages/publications/85055818232
U2 - 10.1038/s41598-018-33843-8
DO - 10.1038/s41598-018-33843-8
M3 - Article
C2 - 30382190
SN - 2045-2322
VL - 8
SP - -
JO - Scientific Reports
JF - Scientific Reports
M1 - 16128
ER -
